Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
The 18F-FDG-PET scan is currently being used for cancer diagnosis, staging, identifying hidden metastasis, and assessment of treatment responses in clinical oncology. Although there are important studies suggesting potential associations between PET-based parameters and oncologic outcomes, the calculation and official documentation of individual PET-based parameters might not be routine in clinical practice because these processes usually require time- and labor-consuming processes for the radiologists. In this study, the investigators prospectively determined clinical 18F-FDG-PET type according to degree of FDG-uptake in pancreatic cancer and compare oncologic outcomes between the types.

Official Title
-----------------
Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer-Prospective Cohort Study

Conditions
-----------------
Pancreatic Cancer

Intervention / Treatment
-----------------
* Device: PET-CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Candidate for radical pancreatectomy due to pancreatic cancer without neoadjuvant treatment Age between 20 years old and 80 years old General performance status greater than 70 Results of peroperative PET-CT available Exclusion Criteria: Unresectable, locally advance and metastatic pancreatic cancer Patients not wanting operation ASA score of greater than 3 History of chronic alcoholism ot drug abuse Lack of patient compliance Patients not agreeing to enroll in the study. Patients unable to understand and sign the study agreement. History of neoadjuvant treatment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| K-type<br>FDG uptake in pancreatic cancer is similar to that of kidney | Device: PET-CT<br>* PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.<br>|
| non K-type<br>FDG uptake in pancreatic cancer is lower than that of kidney | Device: PET-CT<br>* PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical PET type assessed by surgeons from preoperatively preformed PET imaging | Three surgeons will review the preoperative PET imaging and each will determine the clinical PET type as either K-type or Non-K type. Inter-surgeon agreement of clinical PET type will be determined. Clinicopathologic characteristics between K-type and Non-K type will also be analyzed. | 1 week after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with recurrence of cancer or mortality from cancer following operation |  | 3 years |